In case we needed reminding, age-related neurodegenerative diseases such as Alzheimer’s disease (AD), Parkinson’s disease (PD), and motor neurone disease (MND) have two factors in common: (i) advancing age as the single biggest risk factor and (ii) the fact that they are characterized by neuronal degeneration. A recent article (1) encourages us to focus on some of the similarities of these diseases by demonstrating that features characteristically associated with AD are also commonly found in MND.
In their study (1), the group measured key biomarkers of the amyloid cascade [amyloid precursor protein (APP), transactive response DNA-binding protein 43 (TDP-43), phosphorylated TDP-43 (pho-TDP43), amyloid-beta peptide (Aβ), and amyloid precursor protein-binding protein family B (Fe 65)] immunohistochemically in postmortem samples of the hippocampus of amyotrophic lateral sclerosis (ALS) and ALS–frontotemporal dementia patients. Compared to controls, they report increased levels of APP and Aβ peptide in MND patients; the latter change also correlating with cytoplasmic pho-TDP-43 expression. In addition, they found decreased Fe65 expression and increased expression of pho-tau. Interestingly, these molecular alterations were similar for both ALS and ALS–FTD, albeit more pronounced in the latter group. This indicates that the “amyloid cascade,” resulting in the accumulation of amyloid β, is activated in the hippocampus of patients with ALS and ALS–FTD, and that such activation correlates with alterations in TDP-43.
This is an important finding, because it adds to the growing body of evidence that age-related neurodegenerative diseases, rather than being discrete entities, may in fact be different points on a continuum, and the corollary of this is that they may all have similar underlying mechanisms. Indeed, a brief survey of three age-related neurodegenerative diseases (AD, PD, and MND) reveals that there is much overlap in the features associated with these conditions (Table 1), and that they have more in common than anything else (Figure 1).
Table 1
| Condition | Typical features | Associated features |
|---|---|---|
| AD | 1. Aβ deposition (amyloid plaques), intraneuronal aggregation of pho-tau | 9. Movement disorder |
| 2. Increased amyloid precursor protein (APP), accumulation of Aβ and pho-tau | ||
| 3. Cholinergic dysfunction | ||
| 4. Cognitive changes | ||
| 5. Sustained neuroinflammation | ||
| 6. Accumulation of ubiquitinated proteins | ||
| PD | 5. Sustained neuroinflammation | 3. Cholinergic dysfunction |
| 6. Accumulation of ubiquitinated proteins | ||
| 7a. Intracellular accumulation of α-synuclein amyloid-like fibrils (Lewy bodies) | 4. Cognitive changes | |
| 8. Nigral dopamine loss | ||
| 9. Movement disorder | ||
| MND | 5. Sustained neuroinflammation | 2. Increased APP, accumulation of Aβ and pho-tau |
| 6. Accumulation of ubiquitinated proteins | ||
| 9. Movement disorder | 4. Cognitive changes | |
| 10. C9ORF72 mutation | 7b. Intracellular α-synuclein/SOD1 co-aggregation in amyotrophic lateral sclerosis | |
| 11. Intracellular accumulation of aggregated proteins (TDP-43, FUS, and SOD1) | ||
Typical and associated features of Alzheimer’s disease (AD), Parkinson’s disease (PD), and motor neurone disease (MND).
Numbers refer to the following references: (1) Hinz and Geschwind (2); Aday and Sze (3); (2) Vilemagne et al. (4); Gomez-Pinedo et al. (1); (3) Ballinger et al. (5); Park et al. (6); (4) Brandt et al. (7); (5) Chen et al. (8); Amor et al. (9); (6) Atkin and Paulson (10); Jansen et al. (11); (7a) Uchihara and Giasson (12); (7b) Helferich et al. (13); (8) Kalia and Lang (14); (9) Brandt et al. (7); (10) Ticozzi et al. (15); (11) Guerrero et al. (16).
Figure 1
The paper by Gomez-Pinedo et al. (1) is a timely reminder that researchers should perhaps not get tied up with the details of these individual diseases that are so important for differential diagnoses. Instead, those seeking to illuminate basic underlying mechanisms might do well to pool data for neurodegenerative diseases in the hope that it will point them in the right direction. After all, these conditions have so far defied effective treatment or cure.
Statements
Author contributions
IJ wrote the initial draft. CR revised the initial draft and contributed with further writing. Both collected data from literature and revised the final manuscript.
Acknowledgments
CR acknowledges the funding by the Spanish Ministry of Economy (RTC-2015-3309-1) and Instituto de Salud Carlos III, Spain (CPII16/00058), with cofounding by FEDER.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1
Gomez-PinedoUVillar-QuilesRGalanLMatias-GuiuJBenito-MartinMGuerrero-SolaAet alImmunochemical markers of the amyloid cascade in the hippocampus in motor neuron diseases. Front Psychiatry (2016) 7:195.10.3389/fneur.2016.00195
2
HinzFGeschwindD. Molecular genetics of neurodegenerative dementias. Cold Spring Harb Perspect Biol (2016):a023705.10.1101/cshperspect.a023705
3
AdaySSzeS. Insight of brain degenerative protein modifications in the pathology of neurodegeneration and dementia by proteomic profiling. Mol Brain (2016) 9:92.10.1186/s13041-016-0272-9
4
VilemagneVDoreVBourgetPBurnhamSLawsSSalvadoOet alAβ-amyloid and Tau imaging in dementia. Semin Nucl Med (2017) 47:75–88.10.1053/j.semnuclmed.2016.09.00
5
BallingerEAnathMTalmageDRoleL. Basal forebrain cholinergic circuits and signalling in cognition and cognitive decline. Neuron (2016) 91:1199–218.10.1016/j.neuron.2016.09.006
6
ParkHParkIOhYYangDLeeKChoiHet alSubcortical white matter hyperintensities within the cholinergic pathways of patients with dementia and Parkinsonism. J Neurol Sci (2015) 2015(353):44–8.10.1016/j.jns.2015.03.046
7
BrandtTCaplanLDichgansJDienerHKennardC. Neurological Disorders. Course and Treatment. San Diego, CA: Academic Press (1997).
8
ChenWWZhangXHuangWJ. Role of neuroinflammation in neurodegenerative diseases (review). Mol Med Rep (2016) 13:3391–6.10.3892/mmr.2016.4948
9
AmorSPeferoenLVogelDBreurMvan der ValkPBakerDet alInflammation in neurodegenerative diseases – an update. Immunology (2013) 142:151–66.10.1111/imm.12233
10
AtkinGPaulsonH. Ubiquitin pathways in neurodegenerative disease. Front Mol Neurosci (2014) 7:63.10.3389/fnmol.2014.00063
11
JansenAHReitsEAHolEM. The ubiquitin proteasome system in glia and its role in neurodegenerative diseases. Front Mol Neurosci (2014) 7:73.10.3389/fnmol.2014.00073
12
UchiharaTGiassonBI. Propagation of alpha-synuclein pathology: hypotheses, discoveries, and yet unresolved questions from experimental and human brain studies (review). Acta Neuropathol (2016) 131(1):49–73.10.1007/s00401-015-1485-1
13
HelferichAMRufWPGrozdanovVFreischmidtAFeilerMSZondlerLet alα-Synuclein interacts with SOD1 and promotes its oligomerization. Mol Neurodegener (2015) 10:66.10.1186/s13024-015-0062-3
14
KaliaLVLangAE. Parkinson’s disease. Lancet (2015) 386(9996):896–912.10.1016/S0140-6736(14)61393-3
15
TicozziNTilocaCCaliniDGagliardiSAltieriAColombritaCet alC9orf72 repeat expansions are restricted to the ALS-FTD spectrum. Neurobiol Aging (2014) 35(4):e13–7.10.1016/j.neurobiolaging.2013.09.037
16
GuerreroENWangHMitraJHegdePMStowellSELiachkoNFet alTDP-43/FUS in motor neuron disease: complexity and challenges. Prog Neurobiol (2016) 145-146:78–97.10.1016/j.pneurobio.2016.09.004
Summary
Keywords
neurodegenerative diseases, aging, common features, amyloid cascade, translational medical research
Citation
Johnson IP and Roodveldt C (2017) Commentary: Immunochemical Markers of the Amyloid Cascade in the Hippocampus in Motor Neuron Diseases. Front. Neurol. 8:105. doi: 10.3389/fneur.2017.00105
Received
23 January 2017
Accepted
02 March 2017
Published
20 March 2017
Volume
8 - 2017
Edited by
Tibor Hortobágyi, University of Debrecen, Hungary
Reviewed by
Patrick Vourc’H, Institut national de la santé et de la recherche médicale (INSERM), France
Updates
Copyright
© 2017 Johnson and Roodveldt.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Ian Paul Johnson, ian.johnson@adelaide.edu.au
Specialty section: This article was submitted to Neurodegeneration, a section of the journal Frontiers in Neurology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.